Grant McArthur, Australia on vemurafenib + cobimetinib in BRAFV600-positive advanced melanoma...

Interview with
Stefan Zimmermann
ESMO Expert on
Lung Cancer...

“Mesothelioma remains a difficult disease to find better treatment options for, so we asked whether high-dose hemithoracic radiotherapy would decrease the rate or delay the time of local recurrence after chemotherapy and radical surgery,” says lead author Prof Rolf A. Stahel, from the Clinic and Policlinic for Oncology, at the University Hospital Zurich, Switzerland, and current President of the European Society for Medical Oncology. The ...

Tony Mok, China...

Evandro de Azambuja, Brussels...

Gefitinib is a type of drug known as a tyrosine kinase inhibitor, and it targets cells with EGFR mutations. Most patients with EGFR mutation-positive non-small cell lung cancer respond to first-line EGFR tyrosine kinase inhibitors, but later acquire resistance. The primary objective of the trial was to show whether there was a difference in progression-free survival when gefitinib was continued in this situation. “This study was designed to ...

The results come from an online survey of 895 doctors from 12 countries in Europe, South America and Asia. All were practicing oncology specialists, with more than three years’ experience, treating more than fifteen patients a month. While 82% of those surveyed believed that deciding on a course of treatment is a process that should be shared between doctors and the patient, fewer than 23% of physicians believed their patients were always fully ...

Women are indeed increasingly choosing oncology specialties in Greece, however, most decision-making posts are still dominated by men across the profession, in private practice, academia and national health environments. This needs to change, she said. The survey of 80 female members of the Hellenic Societies of Medical, Radiation and Surgical Oncology showed that while women were widely represented in workplaces, team leaders were men in 82% of ...

A pertuzumab hozzáadása a trasztuzumab terápiához 56,5 hónapos teljes túlélést eredményez HER2-pozitív metasztatikus emlőkarcinómában. Ez az eddigi leghosszabb túlélés előrehaladott emlőrákban folytatott fázis III vizsgálatban. A CLEOPATRA vizsgálatban 808, korábban kezeletlen, HER2-pozitív, metasztatikus emlőrákban szenvedő betegen értékelték a pertuzumab, trasztuzumab és kemoterápia hatékonyságát és ...

2014. október 16. New York-palota, Fehér-Vörös Szalon
1073 Budapest, Erzsébet körút 9–11. ...

Melanoma and colorectal cancer are the main field of progress
Johann de Bono
ESMO 2014
Scientific Chair...

Jean-Pascal Machiels, Belgium...

Thymidylate synthase is one of the proteins that is targeted by pemetrexed which is the most widely used chemotherapeutic regimen in the treatment of non-squamous NSCLC,” explains study author Professor Myung-Ju Ahn, from the Section of Hematology-Oncology at Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. “In this study, we tried to evaluate whether expression of thymidylate synthase is a predictive ...

The study included all residents aged between 50 and 74 years of age who had a first adenoma identified between January 1997 and December 2008. The researchers showed that 38.7% of these people had high-risk adenomas --meaning they were larger than 1 centimetre in diameter, involved the finger-like projections called villi in the intestinal lining, or exhibited a high grade of dysplasia....

At the ESMO 2014 Congress in Madrid, Dr Young-Chul Kim from Chonnam National University Medical School, South Korea, reported the results of an open-label phase III trial that included 149 patients with non-squamous non-small cell lung cancer (NSCLC) conducted at 14 centres in South Korea. “We wanted to conduct this study because pemetrexed plus platinum chemotherapy is the most commonly used regimen for treating patients with non-squamous...

Floriana Morgillo, ESMO Expert on Lung Cancer...

Access to potentially life-extending cancer drugs varies significantly in different regions of the world, new studies show at the ESMO 2014 Congress in Madrid, Spain. Researchers say the results demonstrate the need for better collaboration between doctors and health authorities on an international scale, to ensure patients have access to the best treatments.

Coordinated action is needed at an international level to ensure new cancer-fighting ...

More than 70% of young, European cancer specialists are showing signs of burnout, the largest survey of its kind has revealed. The results, reported at the Congress of ESMO 2014 in Madrid, have prompted calls for serious action to address the issue at all levels. ...

Dr Felipe Ades Moraes from Institut Jules Bordet in Brussels, Belgium and colleagues presented their disappointing findings on trastuzumab access in Eastern-Europe at ESMO 2014 Congress in Madrid, Spain. The authors found that patients in Eastern Europe had less access to the HER2 positive breast cancer targeted drug trastuzumab than their counterparts in Western Europe and the USA; differences they say can be linked to discrepancies in cancer ...